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Objectives: Endovascular repair of abdominal aortic aneurysms, while advantageous because of its minimally invasive
nature, falls short of achieving the long-term durability of traditional open surgical repair. Problems such as device
migration, continued sac pressurization from endoleak, and graft limb thrombosis culminate in a high rate of secondary
procedures and failure to protect against aneurysm rupture. While prior studies hint at a correlation between these
postprocedural events and specific device design, a single comparative analysis that correlates device attributes with
clinical outcome has not been performed.
Methods: Over 6 years ending in 2002, 703 patients underwent endovascular treatment of infrarenal abdominal aortic
aneurysms. During this time, five devices were used, ie, Ancure, AneuRx, Excluder, Talent, and Zenith, and six
device-specific groups were analyzed; the Zenith group was subdivided into those placed as part of the multicenter trial
(Zenith-MCT) and those under a sponsor-investigator investigational device exemption trial (Zenith-SIT). Results were
assessed with the Kaplan-Meier method for censored data, and the log-rank test was used to ascertain differences between
device groups.
Results: While overall survival was diminished in the Zenith-SIT group (P  .046), risk for aneurysm-related death was
similar in all groups (P  .336), averaging 2% or less at 12 months. Among the total cohort of patients, freedom from
rupture was 98.7%  0.9% at 24 months, without demonstrable differences between groups (P  .533). There were no
statistically significant differences in rate of secondary procedures, conversion to open repair, or migration. There were,
however, significant differences in risk for graft limb occlusion and rate of endoleak between groups. Limb occlusion
occurred most often with Ancure devices (11% 4.6% at 12 months, P .009). Endoleak of any type was most common
with Excluder devices (64%  11% at 12 months, P  .003), a finding directly related to increased frequency of type II
leaks in that group (58%  11% at 12 months, P  .001). While there were no differences in frequency of type I or type
III endoleak, a trend toward increased risk for microleak was observed with AneuRx devices (4.0% 1.3%, P .054), and
more modular separations were observed with Zenith devices (3.5%  2.3%, P  .032). Shrinkage at 12 months
correlated with frequency of endoleak in the device groups, and was most common in the two Zenith groups (54% 7.3%
in the Zenith-MCT group and 56%  7.8% in the Zenith-SIT group) and the Talent group (52%  9.7%) and was least
in the Excluder group (15%  7.9% at 12 months, P < .001). By contrast, sac growth occurred most often in the
Zenith-SIT group (13%  4.5% at 12 months, P  .034), possibly as a result of the challenging aortoiliac anatomy
frequently present in these patients.
Conclusions: There are significant differences in frequency of limb occlusion and endoleak between groups with different
endovascular devices. Knowledge of these and other differences is instructional in development of next-generation
endovascular devices, incorporating design features linked to satisfactory outcome while abandoning those associated
with device failure. (J Vasc Surg 2003;37:991-8.)
Endovascular abdominal aortic aneurysm repair has
gained acceptance as a minimally invasive alternative to
open surgery in selected patients. While long-term durabil-
ity remains uncertain, patients and their physicians are
willing to accept a degree of uncertainty in exchange for
dramatic reduction in duration of hospital stay, need for
blood transfusion, and postoperative recovery time.
A number of endovascular devices have been evaluated
in clinical trials designed to gain approval from governmen-
tal regulatory agencies. These devices differ with respect to
design features, including modularity; metallic composi-
tion and structure of the stent; thickness, porosity, and
chemical composition of the polymeric fabric; method of
attaching the fabric to the stent; and presence or absence of
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an active method of fixing the device to the aortic wall with
barbs or hooks.
With consideration of the numerous structural varia-
tions between different brands of endovascular devices, it
would be remarkable if clinical outcome were not equally
dissimilar. Parameters such as frequency of endoleak, long-
term change in size of aneurysm sac, risk for device migra-
tion, and limb thrombosis might be linked to specific device
design features. Evaluation of attributes that correlate with
particular outcome parameters is prerequisite to under-
standing the mechanism of device failure. Such information
will provide a basis for the design of next-generation de-
vices, ultimately resulting in reduced incidence of untoward
events associated with predicate devices.
METHODS
Over 6 years ending in March 2002, 703 patients
underwent endovascular repair of infrarenal abdominal aor-
tic aneurysm. This cohort represents those patients in the
department registry, cross-checked with patient lists from
all clinical endograft trials performed at the institution,
billing records, operating room database, and individual
surgeon case lists. The number of procedures performed
per year and the brands of devices implanted varied over
time (Table I). After early reliance on Ancure (Guidant,
Menlo Park, Calif) and AneuRx (Medtronic/AVE, Santa
Rosa, CA) prostheses, in later years we made the transition
to increased use of the Zenith device (Cook, Bloomington,
Ind). Devices that were rarely used, tube-configured de-
vices, aortomonoiliac devices, and devices placed because of
symptomatic or ruptured aneurysm were included in a
category entitled “Other” and were excluded from analyses
comparing individual device groups. Overall, 555 patients
(79%) were enrolled in investigational device exemption
(IDE) trials, 362 (51%) as part of multicenter corporate-
sponsored clinical evaluations and 193 (27%) under single-
institution sponsor-investigator IDE studies. Commer-
cially available devices were placed in the remaining 148
patients (21%). Elective procedures were performed in 683
patients (97%), and 20 patients (2.8%) underwent urgent
repair of symptomatic (17 patients, 2.4%) or frankly rup-
tured aneurysm (3 patients, 0.4%). Among the 703 devices
placed, 380 (54%) had a suprarenal component and 82
(12%) extended into the external iliac arteries after hypo-
gastric artery embolization. Results were analyzed after
creation of device groups that comprised patients who
received the Ancure device, the AneuRx device, the Ex-
cluder device (W. L. Gore and Associates, Flagstaff, Ariz),
the Zenith device, and the Talent device (Medtronic, Sun-
rise, Fla). The selection of one brand over another was
based on device availability at the time of the procedure and
on eligibility criteria for patients in IDE trials. Ultimately,
however, the choice of device was left to the discretion of
the operating physician. Patients who received Zenith de-
vices were subdivided into those whose devices were placed
as part of a multicenter clinical trial (pivotal and continuing
access phases, Zenith-MCT) and those who were part of a
sponsor-investigator IDE trial (Zenith-SIT). This subdivi-
sion was thought necessary because of differing anatomic
eligibility criteria in patients in sponsor-investigator IDE
trials; this group comprised patients who were ineligible for
the multicenter trial or for commercially available devices
because of anatomic exclusionary criteria such as aortic
neck length, tortuosity, and diameter. Nevertheless, the
length, diameter, and angulation of the infrarenal aortic
neck were statistically similar in the six device groups (Table
II).
As a routine, patients underwent preoperative helical
computed tomography (CT) with a specified imaging pro-
tocol that included 3 mm axial reconstructions; occasion-
Table II. Baseline anatomic variables in six device groups
Device
Angulation
(degree)
Length
(mm)
Diameter
(mm)
Ancure 52  35 37  14 25  7
AneuRx 43  27 35  16 25  6
Excluder 30  7 28  14 25  1
Talent 34  16 33  21 28  4
Zenith-MCT 40  25 31  16 25  3
Zenith-SIT 45  25 29  18 28  5
Data represent mean  SD.
Table I. Endovascular devices placed
Device Total 1996* 1997 1998 1999 2000 2001 2002†
Ancure 63 1 4 0 0 33 16 9
AneuRx 203 0 11 57 70 52 11 2
Excluder 25 0 0 0 11 6 8 0
Talent 39 0 0 0 11 28 0 0
Zenith-MCT‡ 144 0 0 0 0 52 73 19
Zenith-SIT§ 181 0 0 0 10 66 99 6
Other 48 4 5 1 4 20 11 3
Total 703 5 20 58 106 257 218 39
*Only March-December 1996 included.
†Only January-March 2002 included.
‡Patients treated as part of multicenter trials.
§Patients treated in sponsor-investigator investigational device exemption trials.
Includes Aortic tube devices, devices placed in symptomatic or ruptured aneurysms, and devices placed infrequently.
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ally, however, studies were performed that did not conform
to this protocol. Preoperative angiography and intravascu-
lar ultrasound were used when length or diameter measure-
ments were deemed inaccurate on the basis of CT findings,
in the presence of suspected renal or iliac occlusive disease,
or when the endograft was placed as part of a clinical trial
that mandated these studies. Three-dimensional CT recon-
structions were rarely obtained. When the endovascular
repair was performed as part of a clinical trial, institutional
review board approval was obtained, as was appropriate
patient consent in every case. When the procedure was
performed with a commercially available device, patient
consent was obtained and follow-up adhered to the insti-
tutional standard of care, which paralleled most of the
clinical trial protocols (Table III). In all cases, postoperative
follow-up was rigorous, with strict attention to timing and
quality of imaging studies. Four-view plain radiographs
were obtained at each follow-up visit and were evaluated for
modular disunion. Except in patients with contraindica-
tions such as renal insufficiency or history of severe allergy
to contrast media, postoperative CT scans included non-
contrast-enhanced, contrast-enhanced, and 3-minute to 5-
minute delayed post-contrast-enhanced images.
Data were collected from a review of radiology imaging
reports and physician chart notes. Any substantial discrep-
ancy in these two data sources prompted interrogation of
the source imaging studies. Imaging studies performed at
outside institutions were excluded from data analysis when
the interpretation on the radiology report differed from the
physician chart notes or the films were unavailable for
review. Outcome reporting adhered to standards outlined
by the Ad Hoc Committee for Standardized Reporting
Practices in Vascular Surgery of The Society for Vascular
Surgery/American Association for Vascular Surgery (SVS/
AAVS).1 Deaths that occurred within 30 days of the index
procedure were categorized as operative deaths, and deaths
that occurred after 30 days were considered late deaths. An
attempt was made to classify each operative death as proce-
dure-related or device-related. Late deaths were classified as
aneurysm-related or unrelated, where aneurysm-related
deaths included those deaths that occurred as a result of
aneurysm rupture or after any primary or secondary proce-
dure performed to treat the aneurysm or complications
thereof.
Risk for endoleak was defined in binary fashion for each
type of endograft, expressed with Kaplan-Meier method
analysis of the binary event determined by the presence or
absence of an endoleak over the entire period of patient
observation. Endoleak was classified on the basis of serial
imaging studies.2,3 CT findings, although most influential,
composed only one factor. Presumed type I leak observed
on CT scans was invariably followed up with angiographic
confirmation. A leak was considered type II when contrast
medium collection was posterior or at the orifice of the
inferior mesenteric artery. Type II and type IV endoleak
noted only on an intraoperative or pre-discharge imaging
study were excluded from analysis. Leakage through en-
larged suture holes or fabric tears was classified as type III
endoleak, as were defects related to separation of modular
components.4 Endoleak was suspected to be type III when
it directly abutted the graft fabric or was associated with
obvious disunion of components; half of these were con-
firmed at angiography or open surgical conversion.
Migration was defined with clinical and radiographic
parameters, as suggested by the SVS/AAVS document on
endovascular reporting standards.1 Migration included
caudal movement of the proximal attachment site or cranial
movement of a distal attachment site. A device was consid-
ered to have migrated if at least 10 mm of movement was
noted relative to anatomic landmarks; a patient experienced
symptoms from migration, irrespective of distance; or a
secondary intervention was undertaken to remedy migra-
tion-related problems, irrespective of distance.
Aneurysm shrinkage or growth was determined with a
pre-procedural CT scan obtained 3 months or less before
the date of the procedure, as baseline. Size was measured on
the CT scan, using the greatest minor sac dimension on any
axial image. A pre-discharge imaging study was used as the
reference scan when a preoperative study was not available.
This was deemed an acceptable compromise, given almost
identical pre-procedure and pre-discharge sac diameter
measurements (53.8  10.3 mm and 54.2  10.2 mm,
respectively) in patients for whom both studies were avail-
able for analysis. Aneurysm shrinkage was defined as de-
crease of 5 mm or more in the minor dimension of the sac;
enlargement was defined as increase of 5 mm or more in
this dimension.
All binary outcome events that necessarily incorporated
some element of censoring were analyzed with the Kaplan-
Meier method. These end points included death, aneu-
rysm-related death, rupture, secondary procedure, conver-
sion to open surgical repair, limb occlusion, migration,
endoleak (all types individually and in composite), modular
component disunion, sac shrinkage, and sac enlargement.
The Cox-Mantel log-rank test was used to compare differ-
ences between a set of six device-specific Kaplan-Meier
method curves after excluding patients who received “Oth-
er,” rarely used devices not incorporated in the six groups.
No two curves were evaluated for differences between each
other. Noncensored outcome measures such as immediate
postoperative parameters were evaluated with an exact test.
Table III. Follow-up protocol comprising institutional
standard of care
Item Timing
History and physical
examination
Preoperative and at discharge, 1 month,
6 months, 12 months, and yearly
thereafter
Four-view abdominal
plain x-ray films*
At discharge, 1 month, 6 months, 12
months, and yearly thereafter
Helical CT scans Within 3 months of repair and at
discharge, 1 month, 6 months, 12
months, and yearly thereafter
*Before 1999, abdominal plain radiographs were obtained in two planes
only, ie, anteroposterior and lateral.
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Significance was assumed at P  .05 (two-tailed test).
Values are expressed as mean  SE unless otherwise speci-
fied.
RESULTS
The 605 male patients (86%) and 98 female patients
(14%) ranged in age from 48 to 100 years (mean, 75 0.3
years). Average diameter of the aneurysm sac was 54  10
mm and 58  11 mm in minor and major dimensions,
respectively. Operative (30-day) mortality was 1.7% over-
all (12 patients), 1.0% in those treated electively (7 pa-
tients), and 19% in those treated urgently (5 patients). Of
12 operative deaths, 10 (83%) were procedure-related and
resulted from perioperative medical complications, and 2
(17%) were device-related and a direct result of complications
from the device. Median duration of follow-up was 11 months
(range, 0-65 months). Patient survival was 90%  1.4% at 1
year, 78%  2.6% at 2 years, and 49%  6.9% at 5 years
(Kaplan-Meier method). The Zenith-SIT group had a signif-
icantly lower survival rate (85%  3.1% at 12 months, P 
.046); survival was similar in the other five groups (Fig 1).
Aneurysm-related complications. Aneurysm-related
death occurred in 12 patients (1.7%), accounting for 16% of
74 total deaths. There were no device-specific differences in
risk for aneurysm-related death (P .336), averaging 2% or
less in all electively treated patients at 12 months (Kaplan-
Meier method). Three aneurysms ruptured after device
implantation, at 4, 7, and 19 months, for a rupture-free
probability of 98.7%  0.9% at 24 months. Two ruptured
aneurysms occurred in patients with Zenith devices (Ze-
nith-MCT and Zenith-SIT, 1 each); the third rupture
occurred in a patient with a post-commercialization An-
euRx device. In the patients with Zenith devices, ruptures
occurred as a result of dislodgement of the right iliac limb
from its distal attachment site in one patient (Zenith-MCT)
and from development of a false aneurysm at the proximal
attachment site (Zenith-SIT), the exact cause of which was
unclear. In the patient with the AneuRx device, rupture
occurred as a result of separation between a proximal
extender cuff and the main body of the device. The two
ruptured aneurysms attributable to component separation
and from iliac limb dislodgement occurred in patients with
rapidly shrinking aneurysms, each by almost 2 cm in diam-
eter over less than 12 months of observation. Of the 3
patients with ruptured aneurysms, 2 underwent open sur-
gical conversion (1 with AneuRx and 1 with Zenith-MCT)
and 1 died perioperatively (AneuRx); in the third patient
treatment with an endovascular intervention (Zenith-SIT)
was successful.
Secondary procedures were necessary in 104 patients
(15%), and 8 patients (7.7%) died as a result of the inter-
vention. The 12-month risk for necessity of a secondary
procedure did not differ between device groups (P .333),
ranging from 8.8%  2.1% in the AneuRx group to 20% 
5.6% in the Zenith-MCT group (Fig 2). Conversion to
open surgical repair was required in 13 patients (1.9%), and
2 of these patients died (15%). The risk for conversion did
not differ significantly between devices (P  .075). Graft
limb occlusion was detected in 19 patients (2.7%), most
frequently in the Ancure group (11% 4.6% at 12 months,
P  .009; Fig 3). Late limb occlusions were rare; no new
Fig 1. Patient survival over mid-term follow-up in six patient
groups.
Fig 2. Freedom from secondary procedures, defined as all aneu-
rysm-related operations or endovascular interventions performed
after initial endovascular repair.
Fig 3. Freedom from graft limb occlusion over mid-term fol-
low-up.
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Ancure-related limb occlusions were observed after 4
months. Device migration occurred in 25 patients (3.6%).
The 12-month risk for migration ranged from zero (An-
cure, Excluder, and Talent devices) to 8.2%  4.3% (Ze-
nith-MCT), differences that did not attain statistical signif-
icance (P  .237).
Endoleak. Endoleak of any type and observed at any
time after discharge was documented in 162 patients
(23.0%). With the Kaplan-Meier method, the risk for de-
veloping an endoleak was 22% 1.9% at 6 months, 30%
2.3% at 12 months, and 42%  3.4% at 24 months after
implantation. There were device-specific differences in fre-
quency of endoleak of any type (P .003; Fig 4), with the
highest 12-month rate in patients with the Excluder device
(64% 11%) and the lowest 12-month rate in patients with
the Talent (19%  7.1%), Ancure (25%  7.9%), and
Zenith-MCT (27%  5.4%) devices.
Type I leak was documented in 21 patients (3.0%), type
II leak in 130 patients (18%), and type III leak in 16
patients (2.3%). Type I leak was confirmed arteriographi-
cally in all but 2 patients (9.5%), who were deemed too ill to
undergo further tests. Type II leak was, by and large,
documented on follow-up CT scans and confirmed at
subsequent arteriography in only 44 patients (34%). When
analyzed according to specific type of leak, significant dif-
ferences were noted between the device groups. Frequency
of type II leak (Fig 5) was greatest in patients with the
Excluder device (58%  11% at 12 months) and least in
patients with the Talent device (19% 7.1% at 12 months;
P  .001). Frequency of type I leak did not differ signifi-
cantly between groups (P  .332).
There was no difference in overall frequency of type III
leak between device groups (P  .724). Among type III
leaks, 6 were due to disunion of modular components
(38%), 5 of which were confirmed at arteriography and 1 on
plain films and CT scans. The remaining 10 type III leaks
(63%) were classified as microleaks; 7 of these (70%) were
presumed to be such on the basis of serial CT scans, and 3
(30%) were confirmed at graft explantation. Although there
were no intragroup differences in frequency of type III leak,
device-specific differences were documented when these
leaks were subdivided into microleaks or component dis-
union. Of endoleaks classified as microleaks, 8 of 10 (80%)
occurred with AneuRx devices, and 4 of 6 component
disunions (67%) occurred at the junction of the main body
and the iliac limb in patients with Zenith devices (Zenith-
MCT, 3; Zenith-SIT, 1). With the Kaplan-Meier method,
the risk for developing a microleak trended marginally
greater with AneuRx devices compared with other devices
(4.0% 1.3% vs 0.8% 0.6% at 12 months), although the
difference did not attain statistical significance (P  .054).
Risk for component disunion was greater with both Zenith
devices than with other devices (3.5% 2.3% vs zero at 12
months, P  .032).
Aneurysm shrinkage and growth. Sac shrinkage of 5
mm or more occurred in 8.3% 1.4% of patients at 6
months, 39% 2.7% at 12 months, 60% 3.2% at 2 years,
and 68%  3.6% at 3 years after aneurysm repair. Sac
enlargement was observed in 1.8%  0.7% of patients at 6
months, 3.5% 1.0% at 12 months, 11% 2.5% at 2 years,
and 21% 4.5% at 3 years after repair. There were dramatic
Fig 5. Freedom from type II endoleak over mid-term follow-
up.
Fig 6. Proportion of patients without aneurysm shrinkage, de-
fined as decrease in sac diameter of 5 mm or greater.
Fig 4. Freedom from endoleak of any type over mid-term fol-
low-up.
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differences in the rate of sac shrinkage in the six device
groups (Fig 6; P .0001). At 12 months, frequency of sac
shrinkage was greatest in patients with Zenith devices (Ze-
nith-MCT, 54% 7.3%; Zenith-SIT, 55% 7.8%) and the
Talent device (52%  9.7%), and was least in patients with
the Excluder device (15%  7.9%). Ancure and AneuRx
devices were associated with an intermediate rate of shrink-
age (average, 43%  9.6% and 29%  3.7%, respectively).
There were device-specific differences in frequency of sac
enlargement as well (Fig 7; P .034). The frequency of sac
enlargement was highest in the Zenith-SIT group (13% 
4.5% at 12 months). The frequency of enlargement was
relatively low in the other groups, averaging 5% or less at 12
months. Among 32 enlarging aneurysms in the series, no
endoleak was found in 7 (22%).
DISCUSSION
Since the inception of endovascular aneurysm repair
more than a decade ago by Juan Parodi, engineers, investi-
gators, and clinicians have recognized that specific design
elements seem to correlate with development of particular
post-procedural complications.5 For example, early in the
development of endovascular devices Parodi et al6 appreci-
ated that a distal stent was necessary to prevent leakage at
the distal attachment site of straight-tube configuration
endografts. Shortly thereafter, use of tube endografts was
abandoned in all patients except those with the most ideal
distal aortic necks. Similarly, the absence of fully supported
endograft limbs was associated with an increased rate of
limb thrombosis, forcing the use of adjuvant stenting of the
graft limbs in many patients.7 By contrast, a rigid endograft
skeleton does not conform to tortuous anatomy and seems
to promote dislodgement of proximal or distal components
from their attachment sites when aneurysm morphologic
changes develop over time.8,9
The present study sought to analyze the long-term
results with various endograft devices to determine design
features that might correlate with particular modes of fail-
ure. Its retrospective nature and inextricable issues of pa-
tient selection variability between device groups, however,
potentially confound such analysis; comparability of base-
line characteristics between groups with the various devices
can never be assured. It is likely that a particular device was
selected to treat specific anatomic configurations, poten-
tially biasing outcome for or against that device. In addi-
tion, definitions used in our analysis may differ from those
others have used, rendering comparisons between this and
other studies difficult. Frequency of migration, according
to the definition of the SVS/AAVS Ad Hoc Committee on
Reporting Standards,1 may have been underestimated.
Lack of an adequate imaging algorithm readily applicable
to devices with a suprarenal stent rendered radiologic inter-
pretation of migration difficult. The precise diagnosis of
type of endoleak was imprecise in this study, as in all
endovascular series. Finally, while we had large numbers of
patients with certain devices, other devices were used in
small numbers of patients evaluated over limited follow-up,
escalating the risk for type II statistical error. This must be
considered when addressing the results of our study, espe-
cially with regard to those particular outcome measures
when differences failed by a narrow margin to achieve
statistical significance.
Despite these limitations, the present study provides
some potentially useful data gathered from a relatively large
number of patients with a variety of endovascular devices
over 6 years. This single-institution analysis offers a level of
uniformity in follow-up imaging measurements and clinical
parameters that is not possible in a multicenter trial. The
availability of clinical, angiographic, and CT data represents
a potential advantage over studies based on core laboratory
data, specifically with respect to classification of endoleak.
The ability to integrate information, including dta obtained
at open surgical conversion or after percutaneous interven-
tion, is a substantial benefit of such a study.
Like open aneurysm repair, endovascular repair has one
primary goal: prevention of aneurysm-related death. The
purpose of endovascular repair is self-evident: protection
against aneurysm-related death without the discomfort as-
sociated with a major open surgical procedure. The present
study and prior series have evaluated a broad spectrum of
post-procedural outcome variables, including en-
doleak,10-14 sac diameter,15,16 migration,17,18 secondary
procedures,9,19 and rupture.20,21 Each parameter, how-
ever, even rupture, is merely a surrogate end point for
aneurysm-related death. Such surrogate end points are
necessary because the rate of aneurysm-related death is so
low that demonstration of equivalence or superiority be-
tween treatment groups would require sample sizes too
large to be feasible. With the single exception of the med-
ically compromised Zenith-SIT group, no differences were
detected with respect to death, aneurysm-related death, or
rupture. Lack of device-specific differences in these end
points is not surprising, however. Late mortality rates are
contaminated by the statistical noise of deaths unrelated to
the aneurysm, specifically those occurring as a result of
cardiovascular disease and malignancy.
Fig 7. Freedom from aneurysm enlargement over time, defined
as increase in sac diameter of 5 mm or greater.
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From the patient’s perspective, avoidance of secondary
interventions is eclipsed only by protection from aneurysm
rupture as a noteworthy, clinically relevant end point. No
differences were noted in frequency of secondary proce-
dures or in the requirement for open surgical conversion
between the various device groups. Migration, while pos-
sibly underestimated with the SVS/AAVS reporting stan-
dards, seemed to occur relatively rarely and with similar
frequency between device groups. By contrast, the rate of
limb occlusion was higher in the Ancure group, the only
device without fully stented graft limbs. Ancure limb occlu-
sions tended to occur early, usually within the first few
months after implantation. The device seemed quite dura-
ble beyond that time.
Endoleak after endovascular aneurysm repair has gar-
nered considerable attention in the literature and been
touted as one of the major shortcomings of this treatment
method.12,14,22-25 Whereas investigators have been likely
to discount type II endoleak as a less important predictor of
ultimate clinical outcome,22 type I and type III leaks are
more ominous and are coupled with sac pressurization and
increased risk for aneurysm rupture.2,19 Clearly, it is impor-
tant to define the source of leakage, and this determination
is most accurate when based on thorough analysis of the
clinical course and a complete set of imaging studies for an
individual patient. For example, angiographic findings, re-
sponse to branch vessel embolization, or observations at
endograft explantation compose some of the pertinent
information that enables accurate classification of endoleak.
Accurate categorization of endoleak may be imprecise
when based on core laboratory data, because the reviewer’s
decision rests on a single imaging study at a solitary point in
time. The single-center design of the present study provides
the opportunity to assemble serial clinical and imaging data
from each patient to more precisely determine the type of
endoleak. Moreover, use of the Kaplan-Meier method
averts the shortcomings inherent in analytical techniques
that do not account for censored data, ie, data where the
outcome is unknown when the analysis is conducted. Yet,
intragroup differences we observed in rate of type II en-
doleak were puzzling; in theory, branch vessel leak should
not be device-dependent. We detected a relatively high rate
of such leaks with the Excluder device, but the relatively
small number of our patients with this product generated a
large confidence interval around the point estimate (95%
confidence interval, 37-80 at 12 months).
In contrast to type II leak, type I and type III leaks have
been considered dependent on the structural properties of
a particular device, both with regard to device durability
and ability of the device to accommodate challenging or
changing arterial anatomy. We observed a similar frequency
of type I and type III leak in the various device groups.
Microleak, by contrast, seemed to be device-specific, and
was most common with AneuRx devices. This finding
corroborates anecdotal data that implicate early iterations
of the AneuRx device, particularly the now obsolete stiff-
body design and more porous fabric. We documented small
defects at the site of weave deformation by suture-stent
motion in these cases, some capable of systemic pressuriza-
tion of the aneurysm sac.26,27 The explanation for lower
frequency of microleak in the other device groups may be
related to different design features of these devices. With
the Talent and Zenith devices, a running suture rather than
point tacking is used to secure the fabric to the stent,
minimizing motion and resultant fabric erosion by the
stent. With the Excluder, Teflon tape is used to secure the
stent to the lining expanded polytetrafluoroethylene
(ePTFE) fabric, without sutures of any kind. Last, the
Ancure device may discourage formation of device-related
endoleak by virtue of its unibody design and paucity of
sutures and interfaces between its metallic and fabric com-
ponents; however, the need for adjuvant stenting of Ancure
limbs may nullify some of this design benefit. By contrast,
the rate of type III leak occurring as a result of component
separation seemed higher in the Zenith groups. It is possi-
ble that the relative stiffness of this device may account for
this observation, with forced disconnection of components
during shrinkage of the aneurysm sac. In addition, the
Zenith design relies on juxtaposition of fabric-to-fabric at
the main body-iliac limb junction, possibly accounting for
lowered coefficient of friction and increased susceptibility
to disunion over time.
Aneurysm sac shrinkage is a parameter many continue
to follow as an indicator of failure or success of aneurysm
exclusion.11,28 While sac growth intuitively signifies a prob-
lem, and most would agree that substantial enlargement is
tantamount to a failed procedure, sac shrinkage is a double-
edged sword. Shrinkage is accompanied by morphologic
changes in length and angulation, changes that can poten-
tiate dislodgement of graft components from one another
or from sites of arterial attachment. Two of the three
post-implant ruptures in the present series occurred in the
setting of a rapidly shrinking aneurysm sac. The response of
the aneurysm sac to repair with different devices is instruc-
tive but not surprising. Devices least likely to be associated
with sac shrinkage were the same devices most likely asso-
ciated with endoleak. Devices more likely associated with
high-pressure leak as a result of poor proximal sealing
mechanisms or fabric degeneration will be associated with a
lower rate of sac regression. The demonstration of endoleak
is only the tip of the iceberg in these groups; undetected
intermittent leakage or presence of a thrombus-dependent
pressure-transmitting seal at the proximal neck may under-
lie continued sac pressurization in many more cases than
previously suspected. The observation of a greater rate of
sac enlargement in patients with the Zenith-SIT versus the
Zenith-MCT may underscore this contention. While the
frequency of type I leak in the Zenith-SIT group was not
significantly greater than that in other groups, this group
includes a greater proportion of patients with a short,
angulated proximal aortic neck and challenging iliac anat-
omy. Although purely speculative, it is possible that unde-
tected problems at the proximal and distal sealing sites may
cause continued sac pressurization in some patients, ac-
counting for a greater proportion of patients with aneurysm
growth.
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Attachment site sealing, however, cannot fully explain
the differences between device groups. Fabric permeability
may be implicated as well. For example, the tightly woven
fabric of the Zenith and Talent devices may be more
effective in preventing transgraft flow or pressure transmis-
sion. Similarly, the thin, microporous expanded ePTFE
fabric of the Excluder device might allow transudation of
fluid, a phenomenon that likely explains the observation of
perigraft hygromas after endovascular aneurysm repair29
and may account for the lower frequency of sac shrinkage with
this device. Last, Bertges et al30 have implicated the stent-
fabric structure as an important correlate of sac regression,
hypothesizing that the degree of systolic-diastolic motion of
the fabric correlates with decreasing sac size. While our find-
ings neither substantiate nor refute any of these mechanisms,
it is clear that an as yet undefined relationship exists between
the device, endoleak, and response of the sac after endovascu-
lar aneurysm repair. We chose not to classify expanding aneu-
rysms without demonstrable endoleak as type V leak or “en-
dotension.”31 Among enlarging aneurysms, however,
endoleak was not observed in 22%. Many would consider
endotension present in these cases.
In summary, the various endovascular devices are asso-
ciated with disparate long-term outcome. Events such as
limb occlusion, graft migration, endoleak, and sac enlarge-
ment are likely interrelated and together determine the
requirement for a secondary procedure or open surgical
conversion, and ultimately the frequency of post-repair
aneurysm rupture. Careful analysis of these events is neces-
sary to achieve improved durability in next-generation en-
dografts. Thoughtful study of the failure modes of present
endograft systems is essential to prevent repetition of the
same failure modes in future device iterations.
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